The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 14, 2023

Filed:

Jul. 21, 2022
Applicant:

Montana State University, Bozeman, MT (US);

Inventors:

Blake A. Wiedenheft, Bozeman, MT (US);

Andrew Santiago-Frangos, Bozeman, MT (US);

Anna A. Nemudraia, Bozeman, MT (US);

Artem A. Nemudryi, Bozeman, MT (US);

Assignee:

MONTANA STATE UNIVERSITY, Bozeman, MT (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 9/22 (2006.01); C12N 15/10 (2006.01); C12Q 1/6844 (2018.01); C12Q 1/6806 (2018.01); C12Q 1/6876 (2018.01); C12Q 1/70 (2006.01); C12Q 1/6818 (2018.01); C12Q 1/6853 (2018.01);
U.S. Cl.
CPC ...
C12Q 1/701 (2013.01); C12Q 1/6806 (2013.01); C12Q 1/6818 (2013.01); C12Q 1/6853 (2013.01);
Abstract

The disclosure relates to engineered systems and methods for detecting target nucleic acid in a sample, which may be a complex mixture. The systems and methods may improve sensitivity of target nucleic acid detection by enhancing signal generation. For example, signal generation may be enhanced through programmable capture and concentration of the target nucleic acid using an engineered type III CRISPR complex. Various ancillary nucleases such as Can1, Can2, and NucC are identified and may be used for detection. For example, binding of the engineered type III CRISPR complex may produce products that activate the identified ancillary nucleases. Different activators trigger changes in the substrate specificity of these nucleases. The activated nucleases may be used to detect programmatic detection of the target nucleic in the sample. The systems and methods are shown to detect viral RNA directly from nasopharyngeal swab samples.


Find Patent Forward Citations

Loading…